onr:"swepub:oai:lup.lub.lu.se:5374ff48-06b9-4dc3-ba3c-9ce55ed47a36"
Search: onr:"swepub:oai:lup.lub.lu.se:5374ff48-06b9-4dc3-ba3c-9ce55ed47a36" > Examestane in advan...
- 1 of 1
- Previous record
- Next record
- To hitlist
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
-
- Lindemann, Kristina (author)
- Oslo University Hospital, Norway
-
- Malander, Susanne (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Lund Hospital, Sweden
-
- Christensen, Rene D. (author)
- University of Southern Denmark, Denmark
- show more...
- show less...
- (creator_code:org_t)
- 2014-02-05
- 2014
- English.
- In: BMC Cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 14
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Results: Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95% CI: 2.1-3-1). In the ER positive patients the median overall survival (OS) time was 13.3 months (95% CI: 7.7-18.9), in the ER negative patients the corresponding numbers were 6.1 months (95% CI: 4.1-8.2). Treatment with exemestane was well tolerated. Conclusion: Treatment of estrogen positive advanced or recurrent endometrial cancer with exemestane, an aromatase inhibitor, resulted in a response rate of 10% and lack of progression after 6 months in 35% of the patients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Aromatase inhibitor
- Exemestane
- Endometrial cancer
- Treatment
- Phase II
- study
- Aromatase inhibitor; Exemestane; Endometrial cancer; Treatment; Phase II study
- MEDICINE
Publication and Content Type
- art (subject category)
- ref (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Lindemann, Krist ...
- Malander, Susann ...
- Christensen, Ren ...
- Mirza, Mansoor R ...
- Kristensen, Gunn ...
- Åvall-Lundqvist, ...
- show more...
- Vergote, Ignace
- Rosenberg, Per
- Boman, Karin
- Nordstrom, Britt ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- BMC Cancer
- By the university
- Lund University
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
